Opus Genetics (IRD) Debt Ratio (2019 - 2026)

Opus Genetics (IRD) reported Debt Ratio of 0.02 for Q1 2026, down 93.2% year-over-year from 0.26 in Q1 2025, and down 20.17% quarter-over-quarter from 0.02 in Q4 2025.

Opus Genetics (IRD) Debt Ratio (2019 - 2026) Analysis & Trends

Opus Genetics (IRD) has 5 years of Debt Ratio data on file, last reported at 0.02 in Q1 2026.

  • Debt Ratio for Q1 2026 came in at 0.02, down 93.2% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.02 (down 93.2% YoY), and the FY2025 annual result was 0.02, changed N/A from the prior year.
  • Debt Ratio declined to 0.02 in Q1 2026 per IRD's latest filing, from 0.02 in the prior quarter.
  • Over five years, Debt Ratio peaked at 0.62 in Q3 2025 and troughed at 0.0 in Q3 2023.
  • A 4-year average of 0.18 and a median of 0.02 in 2025 frame the typical range for Debt Ratio.
  • On a YoY basis, Debt Ratio climbed as much as 93.2% in 2026 and fell as far as 93.2% in 2026.
  • A 4-year view of Debt Ratio shows it stood at 0.01 in 2022, then sank by 83.65% to 0.0 in 2023, then surged by 1209.37% to 0.02 in 2025, then dropped by 20.17% to 0.02 in 2026.
  • Business Quant data shows IRD's Debt Ratio at 0.02 in Q1 2026, 0.02 in Q4 2025, and 0.62 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 0.18
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Opus Genetics 355.39 Mn 295.43 Mn - 0.02

Historic Data

Download Data
DateValue
Mar 31, 2026 0.02
Dec 31, 2025 0.02
Sep 30, 2025 0.62
Jun 30, 2025 0.33
Mar 31, 2025 0.26
Sep 30, 2023 0.00
Mar 31, 2022 0.01
Dec 31, 2019 1.52